nodes	percent_of_prediction	percent_of_DWPC	metapath
Ruxolitinib—Night sweats—Progesterone—uterine cancer	0.00667	0.045	CcSEcCtD
Ruxolitinib—Myelosuppression—Dactinomycin—uterine cancer	0.00542	0.0366	CcSEcCtD
Ruxolitinib—BMPR2—artery—uterine cancer	0.00489	0.0134	CbGeAlD
Ruxolitinib—Myelosuppression—Etoposide—uterine cancer	0.00393	0.0265	CcSEcCtD
Ruxolitinib—Bone pain—Progesterone—uterine cancer	0.00376	0.0254	CcSEcCtD
Ruxolitinib—PRKG2—smooth muscle tissue—uterine cancer	0.00372	0.0102	CbGeAlD
Ruxolitinib—PLK3—myometrium—uterine cancer	0.00368	0.0101	CbGeAlD
Ruxolitinib—PRKG2—renal system—uterine cancer	0.00358	0.00981	CbGeAlD
Ruxolitinib—CAMK1—myometrium—uterine cancer	0.00345	0.00944	CbGeAlD
Ruxolitinib—PLK1—uterine cervix—uterine cancer	0.00343	0.00941	CbGeAlD
Ruxolitinib—PLK1—mammalian vulva—uterine cancer	0.003	0.00823	CbGeAlD
Ruxolitinib—PLK1—uterus—uterine cancer	0.00286	0.00784	CbGeAlD
Ruxolitinib—JAK1—myometrium—uterine cancer	0.00283	0.00774	CbGeAlD
Ruxolitinib—DCLK1—myometrium—uterine cancer	0.00283	0.00774	CbGeAlD
Ruxolitinib—PLK3—decidua—uterine cancer	0.00273	0.00748	CbGeAlD
Ruxolitinib—CAMK1—uterine cervix—uterine cancer	0.00268	0.00734	CbGeAlD
Ruxolitinib—PRKCE—female reproductive system—uterine cancer	0.00268	0.00734	CbGeAlD
Ruxolitinib—PLK3—endometrium—uterine cancer	0.00259	0.0071	CbGeAlD
Ruxolitinib—PLK1—female reproductive system—uterine cancer	0.00257	0.00705	CbGeAlD
Ruxolitinib—RPS6KA6—female reproductive system—uterine cancer	0.00257	0.00705	CbGeAlD
Ruxolitinib—CAMK1—decidua—uterine cancer	0.00255	0.007	CbGeAlD
Ruxolitinib—DAPK3—myometrium—uterine cancer	0.00253	0.00694	CbGeAlD
Ruxolitinib—CLK2—myometrium—uterine cancer	0.00251	0.00688	CbGeAlD
Ruxolitinib—PLK3—mammalian vulva—uterine cancer	0.00251	0.00687	CbGeAlD
Ruxolitinib—Infection—Carboplatin—uterine cancer	0.00243	0.0164	CcSEcCtD
Ruxolitinib—CAMK1—endometrium—uterine cancer	0.00242	0.00664	CbGeAlD
Ruxolitinib—BMPR2—myometrium—uterine cancer	0.00236	0.00647	CbGeAlD
Ruxolitinib—CAMK1—mammalian vulva—uterine cancer	0.00235	0.00642	CbGeAlD
Ruxolitinib—Alanine aminotransferase increased—Progesterone—uterine cancer	0.0023	0.0156	CcSEcCtD
Ruxolitinib—JAK1—epithelium—uterine cancer	0.00222	0.00607	CbGeAlD
Ruxolitinib—DCLK3—vagina—uterine cancer	0.00221	0.00604	CbGeAlD
Ruxolitinib—Myelosuppression—Epirubicin—uterine cancer	0.0022	0.0149	CcSEcCtD
Ruxolitinib—JAK1—uterine cervix—uterine cancer	0.0022	0.00602	CbGeAlD
Ruxolitinib—DCLK1—uterine cervix—uterine cancer	0.0022	0.00602	CbGeAlD
Ruxolitinib—PLK3—female reproductive system—uterine cancer	0.00215	0.00588	CbGeAlD
Ruxolitinib—JAK1—smooth muscle tissue—uterine cancer	0.00214	0.00585	CbGeAlD
Ruxolitinib—CAMK2G—myometrium—uterine cancer	0.00212	0.00579	CbGeAlD
Ruxolitinib—DAPK2—uterine cervix—uterine cancer	0.0021	0.00575	CbGeAlD
Ruxolitinib—LRRK2—myometrium—uterine cancer	0.0021	0.00574	CbGeAlD
Ruxolitinib—JAK1—decidua—uterine cancer	0.0021	0.00574	CbGeAlD
Ruxolitinib—Alanine aminotransferase increased—Medroxyprogesterone Acetate—uterine cancer	0.00209	0.0141	CcSEcCtD
Ruxolitinib—LTK—female reproductive system—uterine cancer	0.00207	0.00568	CbGeAlD
Ruxolitinib—JAK1—renal system—uterine cancer	0.00206	0.00563	CbGeAlD
Ruxolitinib—Weight increased—Progesterone—uterine cancer	0.00205	0.0139	CcSEcCtD
Ruxolitinib—Weight decreased—Progesterone—uterine cancer	0.00204	0.0138	CcSEcCtD
Ruxolitinib—Myelosuppression—Doxorubicin—uterine cancer	0.00204	0.0138	CcSEcCtD
Ruxolitinib—Infestation—Progesterone—uterine cancer	0.00201	0.0136	CcSEcCtD
Ruxolitinib—Infestation NOS—Progesterone—uterine cancer	0.00201	0.0136	CcSEcCtD
Ruxolitinib—CAMK1—female reproductive system—uterine cancer	0.00201	0.0055	CbGeAlD
Ruxolitinib—JAK1—endometrium—uterine cancer	0.00199	0.00545	CbGeAlD
Ruxolitinib—Urinary tract infection—Progesterone—uterine cancer	0.00196	0.0132	CcSEcCtD
Ruxolitinib—PLK3—female gonad—uterine cancer	0.00195	0.00535	CbGeAlD
Ruxolitinib—CLK2—uterine cervix—uterine cancer	0.00195	0.00535	CbGeAlD
Ruxolitinib—MARK2—female reproductive system—uterine cancer	0.00195	0.00534	CbGeAlD
Ruxolitinib—PLK3—vagina—uterine cancer	0.00194	0.00532	CbGeAlD
Ruxolitinib—Body temperature increased—Carboplatin—uterine cancer	0.00193	0.0131	CcSEcCtD
Ruxolitinib—JAK1—mammalian vulva—uterine cancer	0.00192	0.00527	CbGeAlD
Ruxolitinib—DCLK1—mammalian vulva—uterine cancer	0.00192	0.00527	CbGeAlD
Ruxolitinib—HIPK2—renal system—uterine cancer	0.00192	0.00526	CbGeAlD
Ruxolitinib—DAPK3—smooth muscle tissue—uterine cancer	0.00192	0.00525	CbGeAlD
Ruxolitinib—ROCK1—epithelium—uterine cancer	0.00191	0.00523	CbGeAlD
Ruxolitinib—Hepatobiliary disease—Progesterone—uterine cancer	0.0019	0.0129	CcSEcCtD
Ruxolitinib—MAP3K7—myometrium—uterine cancer	0.0019	0.00521	CbGeAlD
Ruxolitinib—DAPK2—endometrium—uterine cancer	0.0019	0.0052	CbGeAlD
Ruxolitinib—DAPK3—decidua—uterine cancer	0.00188	0.00515	CbGeAlD
Ruxolitinib—CAMK1D—mammalian vulva—uterine cancer	0.00188	0.00514	CbGeAlD
Ruxolitinib—TYK2—myometrium—uterine cancer	0.00187	0.00512	CbGeAlD
Ruxolitinib—Weight increased—Medroxyprogesterone Acetate—uterine cancer	0.00186	0.0126	CcSEcCtD
Ruxolitinib—CLK2—decidua—uterine cancer	0.00186	0.0051	CbGeAlD
Ruxolitinib—Weight decreased—Medroxyprogesterone Acetate—uterine cancer	0.00185	0.0125	CcSEcCtD
Ruxolitinib—DAPK3—renal system—uterine cancer	0.00185	0.00505	CbGeAlD
Ruxolitinib—MKNK2—myometrium—uterine cancer	0.00184	0.00505	CbGeAlD
Ruxolitinib—ROCK1—smooth muscle tissue—uterine cancer	0.00184	0.00504	CbGeAlD
Ruxolitinib—DAPK2—mammalian vulva—uterine cancer	0.00184	0.00503	CbGeAlD
Ruxolitinib—JAK1—uterus—uterine cancer	0.00183	0.00502	CbGeAlD
Ruxolitinib—DCLK1—uterus—uterine cancer	0.00183	0.00502	CbGeAlD
Ruxolitinib—CLK2—renal system—uterine cancer	0.00183	0.00501	CbGeAlD
Ruxolitinib—CAMK1—female gonad—uterine cancer	0.00183	0.00501	CbGeAlD
Ruxolitinib—Infestation—Medroxyprogesterone Acetate—uterine cancer	0.00182	0.0123	CcSEcCtD
Ruxolitinib—Infestation NOS—Medroxyprogesterone Acetate—uterine cancer	0.00182	0.0123	CcSEcCtD
Ruxolitinib—CAMK1—vagina—uterine cancer	0.00182	0.00498	CbGeAlD
Ruxolitinib—Haemoglobin—Progesterone—uterine cancer	0.00182	0.0123	CcSEcCtD
Ruxolitinib—Haemorrhage—Progesterone—uterine cancer	0.00181	0.0122	CcSEcCtD
Ruxolitinib—BMPR2—smooth muscle tissue—uterine cancer	0.00179	0.0049	CbGeAlD
Ruxolitinib—DAPK3—endometrium—uterine cancer	0.00178	0.00489	CbGeAlD
Ruxolitinib—Urinary tract infection—Medroxyprogesterone Acetate—uterine cancer	0.00177	0.012	CcSEcCtD
Ruxolitinib—ROCK1—renal system—uterine cancer	0.00177	0.00485	CbGeAlD
Ruxolitinib—CLK2—endometrium—uterine cancer	0.00177	0.00484	CbGeAlD
Ruxolitinib—DYRK1A—decidua—uterine cancer	0.00176	0.00482	CbGeAlD
Ruxolitinib—NUAK2—uterine cervix—uterine cancer	0.00176	0.00482	CbGeAlD
Ruxolitinib—BMPR2—decidua—uterine cancer	0.00175	0.0048	CbGeAlD
Ruxolitinib—DYRK1A—renal system—uterine cancer	0.00173	0.00473	CbGeAlD
Ruxolitinib—DAPK3—mammalian vulva—uterine cancer	0.00173	0.00473	CbGeAlD
Ruxolitinib—Hepatobiliary disease—Medroxyprogesterone Acetate—uterine cancer	0.00173	0.0117	CcSEcCtD
Ruxolitinib—BMPR2—renal system—uterine cancer	0.00172	0.00471	CbGeAlD
Ruxolitinib—Epistaxis—Medroxyprogesterone Acetate—uterine cancer	0.00172	0.0116	CcSEcCtD
Ruxolitinib—CLK2—mammalian vulva—uterine cancer	0.00171	0.00468	CbGeAlD
Ruxolitinib—JAK2—myometrium—uterine cancer	0.0017	0.00466	CbGeAlD
Ruxolitinib—NUAK2—decidua—uterine cancer	0.00167	0.00459	CbGeAlD
Ruxolitinib—JAK3—female reproductive system—uterine cancer	0.00166	0.00454	CbGeAlD
Ruxolitinib—JAK1—female reproductive system—uterine cancer	0.00165	0.00451	CbGeAlD
Ruxolitinib—BMP2K—uterine cervix—uterine cancer	0.00165	0.00451	CbGeAlD
Ruxolitinib—CAMK2G—uterine cervix—uterine cancer	0.00165	0.00451	CbGeAlD
Ruxolitinib—Haemoglobin—Medroxyprogesterone Acetate—uterine cancer	0.00165	0.0111	CcSEcCtD
Ruxolitinib—DAPK3—uterus—uterine cancer	0.00164	0.0045	CbGeAlD
Ruxolitinib—TAOK2—female gonad—uterine cancer	0.00164	0.0045	CbGeAlD
Ruxolitinib—MAP3K3—myometrium—uterine cancer	0.00164	0.00449	CbGeAlD
Ruxolitinib—Haemorrhage—Medroxyprogesterone Acetate—uterine cancer	0.00164	0.0111	CcSEcCtD
Ruxolitinib—PLK4—female reproductive system—uterine cancer	0.00164	0.00448	CbGeAlD
Ruxolitinib—TAOK2—vagina—uterine cancer	0.00163	0.00447	CbGeAlD
Ruxolitinib—LRRK2—uterine cervix—uterine cancer	0.00163	0.00447	CbGeAlD
Ruxolitinib—PHKG2—female reproductive system—uterine cancer	0.0016	0.00438	CbGeAlD
Ruxolitinib—NUAK2—endometrium—uterine cancer	0.00159	0.00436	CbGeAlD
Ruxolitinib—Malnutrition—Progesterone—uterine cancer	0.00157	0.0106	CcSEcCtD
Ruxolitinib—BMP2K—decidua—uterine cancer	0.00157	0.0043	CbGeAlD
Ruxolitinib—PRKCE—lymph node—uterine cancer	0.00157	0.00429	CbGeAlD
Ruxolitinib—LRRK2—decidua—uterine cancer	0.00155	0.00426	CbGeAlD
Ruxolitinib—Flatulence—Progesterone—uterine cancer	0.00155	0.0105	CcSEcCtD
Ruxolitinib—STK16—female reproductive system—uterine cancer	0.00155	0.00424	CbGeAlD
Ruxolitinib—HIPK2—female reproductive system—uterine cancer	0.00154	0.00421	CbGeAlD
Ruxolitinib—NUAK2—mammalian vulva—uterine cancer	0.00154	0.00421	CbGeAlD
Ruxolitinib—BMPR2—uterus—uterine cancer	0.00153	0.0042	CbGeAlD
Ruxolitinib—LRRK2—renal system—uterine cancer	0.00153	0.00418	CbGeAlD
Ruxolitinib—Pancytopenia—Dactinomycin—uterine cancer	0.00152	0.0102	CcSEcCtD
Ruxolitinib—JAK3—female gonad—uterine cancer	0.00151	0.00413	CbGeAlD
Ruxolitinib—MAP3K19—female reproductive system—uterine cancer	0.00151	0.00413	CbGeAlD
Ruxolitinib—RPS6KA6—lymph node—uterine cancer	0.00151	0.00412	CbGeAlD
Ruxolitinib—PLK1—lymph node—uterine cancer	0.00151	0.00412	CbGeAlD
Ruxolitinib—JAK1—female gonad—uterine cancer	0.0015	0.00411	CbGeAlD
Ruxolitinib—MAP3K2—uterine cervix—uterine cancer	0.00149	0.00409	CbGeAlD
Ruxolitinib—TAOK3—myometrium—uterine cancer	0.00149	0.00409	CbGeAlD
Ruxolitinib—Neutropenia—Dactinomycin—uterine cancer	0.00149	0.0101	CcSEcCtD
Ruxolitinib—JAK1—vagina—uterine cancer	0.00149	0.00408	CbGeAlD
Ruxolitinib—DCLK1—vagina—uterine cancer	0.00149	0.00408	CbGeAlD
Ruxolitinib—BMP2K—endometrium—uterine cancer	0.00149	0.00408	CbGeAlD
Ruxolitinib—CAMK2G—endometrium—uterine cancer	0.00149	0.00408	CbGeAlD
Ruxolitinib—MAP3K7—uterine cervix—uterine cancer	0.00148	0.00406	CbGeAlD
Ruxolitinib—DAPK3—female reproductive system—uterine cancer	0.00148	0.00405	CbGeAlD
Ruxolitinib—LRRK2—endometrium—uterine cancer	0.00148	0.00404	CbGeAlD
Ruxolitinib—CLK2—female reproductive system—uterine cancer	0.00146	0.00401	CbGeAlD
Ruxolitinib—CAMK1D—female gonad—uterine cancer	0.00146	0.00401	CbGeAlD
Ruxolitinib—PHKG2—female gonad—uterine cancer	0.00145	0.00398	CbGeAlD
Ruxolitinib—CAMK1D—vagina—uterine cancer	0.00145	0.00398	CbGeAlD
Ruxolitinib—TYK2—uterine cervix—uterine cancer	0.00145	0.00398	CbGeAlD
Ruxolitinib—Anaemia—Progesterone—uterine cancer	0.00145	0.00982	CcSEcCtD
Ruxolitinib—MKNK2—epithelium—uterine cancer	0.00145	0.00396	CbGeAlD
Ruxolitinib—MAP3K7—smooth muscle tissue—uterine cancer	0.00144	0.00394	CbGeAlD
Ruxolitinib—IRAK1—uterine cervix—uterine cancer	0.00144	0.00393	CbGeAlD
Ruxolitinib—MKNK2—uterine cervix—uterine cancer	0.00144	0.00393	CbGeAlD
Ruxolitinib—DAPK2—female gonad—uterine cancer	0.00143	0.00392	CbGeAlD
Ruxolitinib—LRRK2—mammalian vulva—uterine cancer	0.00143	0.00391	CbGeAlD
Ruxolitinib—Malnutrition—Medroxyprogesterone Acetate—uterine cancer	0.00143	0.00963	CcSEcCtD
Ruxolitinib—DAPK2—vagina—uterine cancer	0.00142	0.00389	CbGeAlD
Ruxolitinib—ROCK1—female reproductive system—uterine cancer	0.00142	0.00389	CbGeAlD
Ruxolitinib—TYK2—smooth muscle tissue—uterine cancer	0.00141	0.00387	CbGeAlD
Ruxolitinib—RET—epithelium—uterine cancer	0.00141	0.00387	CbGeAlD
Ruxolitinib—MAP3K7—decidua—uterine cancer	0.00141	0.00386	CbGeAlD
Ruxolitinib—STK16—female gonad—uterine cancer	0.00141	0.00385	CbGeAlD
Ruxolitinib—Flatulence—Medroxyprogesterone Acetate—uterine cancer	0.0014	0.00949	CcSEcCtD
Ruxolitinib—HIPK2—female gonad—uterine cancer	0.0014	0.00383	CbGeAlD
Ruxolitinib—STK16—vagina—uterine cancer	0.0014	0.00383	CbGeAlD
Ruxolitinib—MKNK2—smooth muscle tissue—uterine cancer	0.00139	0.00382	CbGeAlD
Ruxolitinib—IRAK1—smooth muscle tissue—uterine cancer	0.00139	0.00382	CbGeAlD
Ruxolitinib—TYK2—decidua—uterine cancer	0.00139	0.00379	CbGeAlD
Ruxolitinib—DYRK1A—female reproductive system—uterine cancer	0.00138	0.00379	CbGeAlD
Ruxolitinib—BMPR2—female reproductive system—uterine cancer	0.00138	0.00377	CbGeAlD
Ruxolitinib—CAMK2G—uterus—uterine cancer	0.00137	0.00376	CbGeAlD
Ruxolitinib—Herpes zoster—Epirubicin—uterine cancer	0.00137	0.00926	CcSEcCtD
Ruxolitinib—IRAK1—decidua—uterine cancer	0.00137	0.00375	CbGeAlD
Ruxolitinib—MKNK2—decidua—uterine cancer	0.00137	0.00375	CbGeAlD
Ruxolitinib—TYK2—renal system—uterine cancer	0.00136	0.00373	CbGeAlD
Ruxolitinib—DAPK3—female gonad—uterine cancer	0.00134	0.00368	CbGeAlD
Ruxolitinib—MKNK2—renal system—uterine cancer	0.00134	0.00368	CbGeAlD
Ruxolitinib—MAP3K7—endometrium—uterine cancer	0.00134	0.00367	CbGeAlD
Ruxolitinib—DAPK3—vagina—uterine cancer	0.00134	0.00366	CbGeAlD
Ruxolitinib—JAK2—epithelium—uterine cancer	0.00133	0.00365	CbGeAlD
Ruxolitinib—RET—decidua—uterine cancer	0.00133	0.00365	CbGeAlD
Ruxolitinib—CLK2—female gonad—uterine cancer	0.00133	0.00365	CbGeAlD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Progesterone—uterine cancer	0.00133	0.00898	CcSEcCtD
Ruxolitinib—CLK2—vagina—uterine cancer	0.00132	0.00363	CbGeAlD
Ruxolitinib—JAK2—uterine cervix—uterine cancer	0.00132	0.00362	CbGeAlD
Ruxolitinib—Anaemia—Medroxyprogesterone Acetate—uterine cancer	0.00132	0.0089	CcSEcCtD
Ruxolitinib—TYK2—endometrium—uterine cancer	0.00132	0.0036	CbGeAlD
Ruxolitinib—RET—renal system—uterine cancer	0.00131	0.00359	CbGeAlD
Ruxolitinib—MKNK2—endometrium—uterine cancer	0.0013	0.00356	CbGeAlD
Ruxolitinib—MAP3K7—mammalian vulva—uterine cancer	0.0013	0.00355	CbGeAlD
Ruxolitinib—ROCK1—female gonad—uterine cancer	0.00129	0.00354	CbGeAlD
Ruxolitinib—JAK2—smooth muscle tissue—uterine cancer	0.00129	0.00352	CbGeAlD
Ruxolitinib—Infection—Progesterone—uterine cancer	0.00128	0.00862	CcSEcCtD
Ruxolitinib—MAP3K3—uterine cervix—uterine cancer	0.00128	0.00349	CbGeAlD
Ruxolitinib—TYK2—mammalian vulva—uterine cancer	0.00127	0.00348	CbGeAlD
Ruxolitinib—Herpes zoster—Doxorubicin—uterine cancer	0.00127	0.00856	CcSEcCtD
Ruxolitinib—JAK2—decidua—uterine cancer	0.00126	0.00345	CbGeAlD
Ruxolitinib—DYRK1A—female gonad—uterine cancer	0.00126	0.00345	CbGeAlD
Ruxolitinib—Nervous system disorder—Progesterone—uterine cancer	0.00126	0.0085	CcSEcCtD
Ruxolitinib—PLK3—lymph node—uterine cancer	0.00126	0.00344	CbGeAlD
Ruxolitinib—IRAK1—mammalian vulva—uterine cancer	0.00126	0.00344	CbGeAlD
Ruxolitinib—MKNK2—mammalian vulva—uterine cancer	0.00126	0.00344	CbGeAlD
Ruxolitinib—BMPR2—female gonad—uterine cancer	0.00125	0.00343	CbGeAlD
Ruxolitinib—Skin disorder—Progesterone—uterine cancer	0.00125	0.00842	CcSEcCtD
Ruxolitinib—BMPR2—vagina—uterine cancer	0.00125	0.00341	CbGeAlD
Ruxolitinib—MAP3K2—uterus—uterine cancer	0.00125	0.00341	CbGeAlD
Ruxolitinib—JAK2—renal system—uterine cancer	0.00124	0.00339	CbGeAlD
Ruxolitinib—MAP3K7—uterus—uterine cancer	0.00123	0.00338	CbGeAlD
Ruxolitinib—CAMK2G—female reproductive system—uterine cancer	0.00123	0.00338	CbGeAlD
Ruxolitinib—BMP2K—female reproductive system—uterine cancer	0.00123	0.00338	CbGeAlD
Ruxolitinib—LRRK2—female reproductive system—uterine cancer	0.00122	0.00335	CbGeAlD
Ruxolitinib—MAP3K3—decidua—uterine cancer	0.00121	0.00333	CbGeAlD
Ruxolitinib—LTK—lymph node—uterine cancer	0.00121	0.00332	CbGeAlD
Ruxolitinib—TYK2—uterus—uterine cancer	0.00121	0.00332	CbGeAlD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Medroxyprogesterone Acetate—uterine cancer	0.00121	0.00814	CcSEcCtD
Ruxolitinib—NUAK2—female gonad—uterine cancer	0.0012	0.00328	CbGeAlD
Ruxolitinib—JAK2—endometrium—uterine cancer	0.0012	0.00328	CbGeAlD
Ruxolitinib—MKNK2—uterus—uterine cancer	0.0012	0.00328	CbGeAlD
Ruxolitinib—NUAK2—vagina—uterine cancer	0.00119	0.00326	CbGeAlD
Ruxolitinib—Alanine aminotransferase increased—Etoposide—uterine cancer	0.00118	0.00796	CcSEcCtD
Ruxolitinib—CAMK1—lymph node—uterine cancer	0.00118	0.00322	CbGeAlD
Ruxolitinib—TAOK3—uterine cervix—uterine cancer	0.00116	0.00318	CbGeAlD
Ruxolitinib—JAK2—mammalian vulva—uterine cancer	0.00116	0.00317	CbGeAlD
Ruxolitinib—Infection—Medroxyprogesterone Acetate—uterine cancer	0.00116	0.00781	CcSEcCtD
Ruxolitinib—MAP3K3—endometrium—uterine cancer	0.00115	0.00316	CbGeAlD
Ruxolitinib—Nervous system disorder—Medroxyprogesterone Acetate—uterine cancer	0.00114	0.00771	CcSEcCtD
Ruxolitinib—MARK2—lymph node—uterine cancer	0.00114	0.00312	CbGeAlD
Ruxolitinib—Thrombocytopenia—Medroxyprogesterone Acetate—uterine cancer	0.00114	0.00769	CcSEcCtD
Ruxolitinib—Skin disorder—Medroxyprogesterone Acetate—uterine cancer	0.00113	0.00763	CcSEcCtD
Ruxolitinib—BMP2K—female gonad—uterine cancer	0.00112	0.00307	CbGeAlD
Ruxolitinib—CAMK2G—female gonad—uterine cancer	0.00112	0.00307	CbGeAlD
Ruxolitinib—MAP3K2—female reproductive system—uterine cancer	0.00112	0.00307	CbGeAlD
Ruxolitinib—MAP3K3—mammalian vulva—uterine cancer	0.00112	0.00306	CbGeAlD
Ruxolitinib—CAMK2G—vagina—uterine cancer	0.00112	0.00306	CbGeAlD
Ruxolitinib—BMP2K—vagina—uterine cancer	0.00112	0.00306	CbGeAlD
Ruxolitinib—LRRK2—female gonad—uterine cancer	0.00111	0.00305	CbGeAlD
Ruxolitinib—Gastrointestinal disorder—Progesterone—uterine cancer	0.00111	0.00749	CcSEcCtD
Ruxolitinib—TAOK3—decidua—uterine cancer	0.00111	0.00303	CbGeAlD
Ruxolitinib—Fatigue—Progesterone—uterine cancer	0.00111	0.00748	CcSEcCtD
Ruxolitinib—LRRK2—vagina—uterine cancer	0.00111	0.00303	CbGeAlD
Ruxolitinib—Pancytopenia—Etoposide—uterine cancer	0.0011	0.00741	CcSEcCtD
Ruxolitinib—TYK2—female reproductive system—uterine cancer	0.00109	0.00298	CbGeAlD
Ruxolitinib—TAOK3—renal system—uterine cancer	0.00109	0.00298	CbGeAlD
Ruxolitinib—Neutropenia—Etoposide—uterine cancer	0.00108	0.00729	CcSEcCtD
Ruxolitinib—Bone pain—Epirubicin—uterine cancer	0.00108	0.00728	CcSEcCtD
Ruxolitinib—MKNK2—female reproductive system—uterine cancer	0.00108	0.00295	CbGeAlD
Ruxolitinib—IRAK1—female reproductive system—uterine cancer	0.00108	0.00295	CbGeAlD
Ruxolitinib—TAOK2—lymph node—uterine cancer	0.00106	0.00289	CbGeAlD
Ruxolitinib—TAOK3—endometrium—uterine cancer	0.00105	0.00288	CbGeAlD
Ruxolitinib—Infestation—Etoposide—uterine cancer	0.00103	0.00696	CcSEcCtD
Ruxolitinib—Infestation NOS—Etoposide—uterine cancer	0.00103	0.00696	CcSEcCtD
Ruxolitinib—Anaemia—Dactinomycin—uterine cancer	0.00103	0.00694	CcSEcCtD
Ruxolitinib—MAP3K2—female gonad—uterine cancer	0.00102	0.00279	CbGeAlD
Ruxolitinib—TAOK3—mammalian vulva—uterine cancer	0.00102	0.00279	CbGeAlD
Ruxolitinib—Body temperature increased—Progesterone—uterine cancer	0.00101	0.00686	CcSEcCtD
Ruxolitinib—MAP3K7—female gonad—uterine cancer	0.00101	0.00277	CbGeAlD
Ruxolitinib—PLK1—Teniposide—Etoposide—uterine cancer	0.00101	0.0875	CbGdCrCtD
Ruxolitinib—PLK4—Teniposide—Etoposide—uterine cancer	0.00101	0.0875	CbGdCrCtD
Ruxolitinib—Gastrointestinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.001	0.00678	CcSEcCtD
Ruxolitinib—MAP3K7—vagina—uterine cancer	0.001	0.00275	CbGeAlD
Ruxolitinib—Fatigue—Medroxyprogesterone Acetate—uterine cancer	0.001	0.00678	CcSEcCtD
Ruxolitinib—Bone pain—Doxorubicin—uterine cancer	0.000997	0.00673	CcSEcCtD
Ruxolitinib—TYK2—female gonad—uterine cancer	0.000991	0.00272	CbGeAlD
Ruxolitinib—JAK2—female reproductive system—uterine cancer	0.000991	0.00271	CbGeAlD
Ruxolitinib—TYK2—vagina—uterine cancer	0.000985	0.0027	CbGeAlD
Ruxolitinib—IRAK1—female gonad—uterine cancer	0.000978	0.00268	CbGeAlD
Ruxolitinib—MKNK2—female gonad—uterine cancer	0.000978	0.00268	CbGeAlD
Ruxolitinib—Hepatobiliary disease—Etoposide—uterine cancer	0.000974	0.00658	CcSEcCtD
Ruxolitinib—MKNK2—vagina—uterine cancer	0.000973	0.00266	CbGeAlD
Ruxolitinib—JAK3—lymph node—uterine cancer	0.00097	0.00266	CbGeAlD
Ruxolitinib—TAOK3—uterus—uterine cancer	0.000969	0.00265	CbGeAlD
Ruxolitinib—JAK1—lymph node—uterine cancer	0.000964	0.00264	CbGeAlD
Ruxolitinib—DCLK1—lymph node—uterine cancer	0.000964	0.00264	CbGeAlD
Ruxolitinib—PLK4—lymph node—uterine cancer	0.000958	0.00262	CbGeAlD
Ruxolitinib—MAP3K3—female reproductive system—uterine cancer	0.000955	0.00262	CbGeAlD
Ruxolitinib—CAMK1D—lymph node—uterine cancer	0.000941	0.00258	CbGeAlD
Ruxolitinib—PHKG2—lymph node—uterine cancer	0.000935	0.00256	CbGeAlD
Ruxolitinib—Asthenia—Progesterone—uterine cancer	0.000921	0.00622	CcSEcCtD
Ruxolitinib—Body temperature increased—Medroxyprogesterone Acetate—uterine cancer	0.00092	0.00621	CcSEcCtD
Ruxolitinib—DAPK2—lymph node—uterine cancer	0.000919	0.00252	CbGeAlD
Ruxolitinib—Pruritus—Progesterone—uterine cancer	0.000908	0.00614	CcSEcCtD
Ruxolitinib—STK16—lymph node—uterine cancer	0.000905	0.00248	CbGeAlD
Ruxolitinib—JAK2—female gonad—uterine cancer	0.000902	0.00247	CbGeAlD
Ruxolitinib—Infection—Dactinomycin—uterine cancer	0.000902	0.00609	CcSEcCtD
Ruxolitinib—HIPK2—lymph node—uterine cancer	0.0009	0.00246	CbGeAlD
Ruxolitinib—JAK2—vagina—uterine cancer	0.000896	0.00246	CbGeAlD
Ruxolitinib—Thrombocytopenia—Dactinomycin—uterine cancer	0.000889	0.006	CcSEcCtD
Ruxolitinib—TAOK3—female reproductive system—uterine cancer	0.000871	0.00239	CbGeAlD
Ruxolitinib—MAP3K3—female gonad—uterine cancer	0.000869	0.00238	CbGeAlD
Ruxolitinib—DAPK3—lymph node—uterine cancer	0.000865	0.00237	CbGeAlD
Ruxolitinib—MAP3K3—vagina—uterine cancer	0.000864	0.00237	CbGeAlD
Ruxolitinib—CLK2—lymph node—uterine cancer	0.000856	0.00235	CbGeAlD
Ruxolitinib—Dizziness—Progesterone—uterine cancer	0.000849	0.00573	CcSEcCtD
Ruxolitinib—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.000835	0.00564	CcSEcCtD
Ruxolitinib—Pruritus—Medroxyprogesterone Acetate—uterine cancer	0.000823	0.00556	CcSEcCtD
Ruxolitinib—DYRK1A—lymph node—uterine cancer	0.00081	0.00222	CbGeAlD
Ruxolitinib—BMPR2—lymph node—uterine cancer	0.000806	0.00221	CbGeAlD
Ruxolitinib—Headache—Progesterone—uterine cancer	0.000804	0.00543	CcSEcCtD
Ruxolitinib—TAOK3—female gonad—uterine cancer	0.000793	0.00217	CbGeAlD
Ruxolitinib—TAOK3—vagina—uterine cancer	0.000788	0.00216	CbGeAlD
Ruxolitinib—Fatigue—Dactinomycin—uterine cancer	0.000782	0.00528	CcSEcCtD
Ruxolitinib—NUAK2—lymph node—uterine cancer	0.000771	0.00211	CbGeAlD
Ruxolitinib—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.000769	0.0052	CcSEcCtD
Ruxolitinib—DYRK1A—Idarubicin—Epirubicin—uterine cancer	0.000768	0.0668	CbGdCrCtD
Ruxolitinib—DYRK1A—Daunorubicin—Epirubicin—uterine cancer	0.000768	0.0668	CbGdCrCtD
Ruxolitinib—DYRK1A—Doxorubicin—Epirubicin—uterine cancer	0.000768	0.0668	CbGdCrCtD
Ruxolitinib—Gastrointestinal haemorrhage—Epirubicin—uterine cancer	0.000749	0.00506	CcSEcCtD
Ruxolitinib—Anaemia—Etoposide—uterine cancer	0.000744	0.00502	CcSEcCtD
Ruxolitinib—Headache—Medroxyprogesterone Acetate—uterine cancer	0.000729	0.00492	CcSEcCtD
Ruxolitinib—CAMK2G—lymph node—uterine cancer	0.000722	0.00198	CbGeAlD
Ruxolitinib—BMP2K—lymph node—uterine cancer	0.000722	0.00198	CbGeAlD
Ruxolitinib—Body temperature increased—Dactinomycin—uterine cancer	0.000717	0.00485	CcSEcCtD
Ruxolitinib—LRRK2—lymph node—uterine cancer	0.000715	0.00196	CbGeAlD
Ruxolitinib—DYRK1A—Idarubicin—Doxorubicin—uterine cancer	0.000711	0.0618	CbGdCrCtD
Ruxolitinib—DYRK1A—Daunorubicin—Doxorubicin—uterine cancer	0.000711	0.0618	CbGdCrCtD
Ruxolitinib—DYRK1A—Epirubicin—Doxorubicin—uterine cancer	0.000711	0.0618	CbGdCrCtD
Ruxolitinib—Gastrointestinal haemorrhage—Doxorubicin—uterine cancer	0.000693	0.00468	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.00068	0.0046	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Epirubicin—uterine cancer	0.000661	0.00446	CcSEcCtD
Ruxolitinib—MAP3K2—lymph node—uterine cancer	0.000655	0.00179	CbGeAlD
Ruxolitinib—Infection—Etoposide—uterine cancer	0.000653	0.00441	CcSEcCtD
Ruxolitinib—Asthenia—Dactinomycin—uterine cancer	0.000651	0.0044	CcSEcCtD
Ruxolitinib—MAP3K7—lymph node—uterine cancer	0.000649	0.00178	CbGeAlD
Ruxolitinib—Thrombocytopenia—Etoposide—uterine cancer	0.000643	0.00434	CcSEcCtD
Ruxolitinib—Skin disorder—Etoposide—uterine cancer	0.000638	0.00431	CcSEcCtD
Ruxolitinib—TYK2—lymph node—uterine cancer	0.000637	0.00175	CbGeAlD
Ruxolitinib—MKNK2—lymph node—uterine cancer	0.000629	0.00172	CbGeAlD
Ruxolitinib—IRAK1—lymph node—uterine cancer	0.000629	0.00172	CbGeAlD
Ruxolitinib—Pancytopenia—Epirubicin—uterine cancer	0.000615	0.00415	CcSEcCtD
Ruxolitinib—RET—lymph node—uterine cancer	0.000614	0.00168	CbGeAlD
Ruxolitinib—Alanine aminotransferase increased—Doxorubicin—uterine cancer	0.000611	0.00413	CcSEcCtD
Ruxolitinib—Neutropenia—Epirubicin—uterine cancer	0.000605	0.00409	CcSEcCtD
Ruxolitinib—Weight increased—Epirubicin—uterine cancer	0.000589	0.00398	CcSEcCtD
Ruxolitinib—Weight decreased—Epirubicin—uterine cancer	0.000586	0.00396	CcSEcCtD
Ruxolitinib—JAK2—lymph node—uterine cancer	0.00058	0.00159	CbGeAlD
Ruxolitinib—Infestation NOS—Epirubicin—uterine cancer	0.000577	0.0039	CcSEcCtD
Ruxolitinib—Infestation—Epirubicin—uterine cancer	0.000577	0.0039	CcSEcCtD
Ruxolitinib—Pancytopenia—Doxorubicin—uterine cancer	0.000569	0.00384	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Etoposide—uterine cancer	0.000567	0.00383	CcSEcCtD
Ruxolitinib—Fatigue—Etoposide—uterine cancer	0.000566	0.00382	CcSEcCtD
Ruxolitinib—Urinary tract infection—Epirubicin—uterine cancer	0.000561	0.00379	CcSEcCtD
Ruxolitinib—Neutropenia—Doxorubicin—uterine cancer	0.00056	0.00378	CcSEcCtD
Ruxolitinib—MAP3K3—lymph node—uterine cancer	0.000559	0.00153	CbGeAlD
Ruxolitinib—Haematuria—Epirubicin—uterine cancer	0.00055	0.00372	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Epirubicin—uterine cancer	0.000546	0.00369	CcSEcCtD
Ruxolitinib—Weight increased—Doxorubicin—uterine cancer	0.000545	0.00368	CcSEcCtD
Ruxolitinib—Epistaxis—Epirubicin—uterine cancer	0.000544	0.00368	CcSEcCtD
Ruxolitinib—Weight decreased—Doxorubicin—uterine cancer	0.000542	0.00366	CcSEcCtD
Ruxolitinib—Infestation NOS—Doxorubicin—uterine cancer	0.000534	0.00361	CcSEcCtD
Ruxolitinib—Infestation—Doxorubicin—uterine cancer	0.000534	0.00361	CcSEcCtD
Ruxolitinib—PLK4—Doxorubicin—Epirubicin—uterine cancer	0.000525	0.0456	CbGdCrCtD
Ruxolitinib—PLK1—Doxorubicin—Epirubicin—uterine cancer	0.000525	0.0456	CbGdCrCtD
Ruxolitinib—PLK1—Idarubicin—Epirubicin—uterine cancer	0.000525	0.0456	CbGdCrCtD
Ruxolitinib—PLK1—Daunorubicin—Epirubicin—uterine cancer	0.000525	0.0456	CbGdCrCtD
Ruxolitinib—PLK4—Idarubicin—Epirubicin—uterine cancer	0.000525	0.0456	CbGdCrCtD
Ruxolitinib—Haemoglobin—Epirubicin—uterine cancer	0.000521	0.00352	CcSEcCtD
Ruxolitinib—Body temperature increased—Etoposide—uterine cancer	0.000519	0.00351	CcSEcCtD
Ruxolitinib—Urinary tract infection—Doxorubicin—uterine cancer	0.000519	0.00351	CcSEcCtD
Ruxolitinib—Haemorrhage—Epirubicin—uterine cancer	0.000518	0.0035	CcSEcCtD
Ruxolitinib—TAOK3—lymph node—uterine cancer	0.00051	0.0014	CbGeAlD
Ruxolitinib—Haematuria—Doxorubicin—uterine cancer	0.000509	0.00344	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Doxorubicin—uterine cancer	0.000505	0.00341	CcSEcCtD
Ruxolitinib—Epistaxis—Doxorubicin—uterine cancer	0.000504	0.0034	CcSEcCtD
Ruxolitinib—PLK1—Idarubicin—Doxorubicin—uterine cancer	0.000486	0.0422	CbGdCrCtD
Ruxolitinib—PLK4—Epirubicin—Doxorubicin—uterine cancer	0.000486	0.0422	CbGdCrCtD
Ruxolitinib—PLK4—Idarubicin—Doxorubicin—uterine cancer	0.000486	0.0422	CbGdCrCtD
Ruxolitinib—PLK1—Daunorubicin—Doxorubicin—uterine cancer	0.000486	0.0422	CbGdCrCtD
Ruxolitinib—PLK1—Epirubicin—Doxorubicin—uterine cancer	0.000486	0.0422	CbGdCrCtD
Ruxolitinib—Haemoglobin—Doxorubicin—uterine cancer	0.000482	0.00326	CcSEcCtD
Ruxolitinib—Haemorrhage—Doxorubicin—uterine cancer	0.00048	0.00324	CcSEcCtD
Ruxolitinib—Asthenia—Etoposide—uterine cancer	0.000471	0.00318	CcSEcCtD
Ruxolitinib—Pruritus—Etoposide—uterine cancer	0.000465	0.00314	CcSEcCtD
Ruxolitinib—Malnutrition—Epirubicin—uterine cancer	0.000451	0.00305	CcSEcCtD
Ruxolitinib—Flatulence—Epirubicin—uterine cancer	0.000445	0.003	CcSEcCtD
Ruxolitinib—Dizziness—Etoposide—uterine cancer	0.000434	0.00293	CcSEcCtD
Ruxolitinib—Malnutrition—Doxorubicin—uterine cancer	0.000417	0.00282	CcSEcCtD
Ruxolitinib—Anaemia—Epirubicin—uterine cancer	0.000417	0.00282	CcSEcCtD
Ruxolitinib—Headache—Etoposide—uterine cancer	0.000411	0.00278	CcSEcCtD
Ruxolitinib—Flatulence—Doxorubicin—uterine cancer	0.000411	0.00278	CcSEcCtD
Ruxolitinib—Anaemia—Doxorubicin—uterine cancer	0.000386	0.00261	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	0.000381	0.00258	CcSEcCtD
Ruxolitinib—Infection—Epirubicin—uterine cancer	0.000366	0.00247	CcSEcCtD
Ruxolitinib—Nervous system disorder—Epirubicin—uterine cancer	0.000361	0.00244	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Epirubicin—uterine cancer	0.00036	0.00243	CcSEcCtD
Ruxolitinib—Skin disorder—Epirubicin—uterine cancer	0.000358	0.00242	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	0.000353	0.00238	CcSEcCtD
Ruxolitinib—Infection—Doxorubicin—uterine cancer	0.000338	0.00229	CcSEcCtD
Ruxolitinib—Nervous system disorder—Doxorubicin—uterine cancer	0.000334	0.00226	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Doxorubicin—uterine cancer	0.000334	0.00225	CcSEcCtD
Ruxolitinib—Skin disorder—Doxorubicin—uterine cancer	0.000331	0.00223	CcSEcCtD
Ruxolitinib—CYP3A4—renal system—uterine cancer	0.00033	0.000905	CbGeAlD
Ruxolitinib—Gastrointestinal disorder—Epirubicin—uterine cancer	0.000318	0.00215	CcSEcCtD
Ruxolitinib—Fatigue—Epirubicin—uterine cancer	0.000317	0.00214	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Doxorubicin—uterine cancer	0.000294	0.00199	CcSEcCtD
Ruxolitinib—Fatigue—Doxorubicin—uterine cancer	0.000294	0.00198	CcSEcCtD
Ruxolitinib—Body temperature increased—Epirubicin—uterine cancer	0.000291	0.00197	CcSEcCtD
Ruxolitinib—Body temperature increased—Doxorubicin—uterine cancer	0.000269	0.00182	CcSEcCtD
Ruxolitinib—CYP3A4—female reproductive system—uterine cancer	0.000265	0.000725	CbGeAlD
Ruxolitinib—Asthenia—Epirubicin—uterine cancer	0.000264	0.00178	CcSEcCtD
Ruxolitinib—Pruritus—Epirubicin—uterine cancer	0.00026	0.00176	CcSEcCtD
Ruxolitinib—Asthenia—Doxorubicin—uterine cancer	0.000244	0.00165	CcSEcCtD
Ruxolitinib—Dizziness—Epirubicin—uterine cancer	0.000243	0.00164	CcSEcCtD
Ruxolitinib—Pruritus—Doxorubicin—uterine cancer	0.000241	0.00163	CcSEcCtD
Ruxolitinib—Headache—Epirubicin—uterine cancer	0.000231	0.00156	CcSEcCtD
Ruxolitinib—Dizziness—Doxorubicin—uterine cancer	0.000225	0.00152	CcSEcCtD
Ruxolitinib—Headache—Doxorubicin—uterine cancer	0.000213	0.00144	CcSEcCtD
Ruxolitinib—JAK3—Signaling Pathways—CXCL8—uterine cancer	1.38e-05	2.9e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—KRAS—uterine cancer	1.38e-05	2.9e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—PIK3CA—uterine cancer	1.37e-05	2.89e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—HRAS—uterine cancer	1.37e-05	2.88e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—HRAS—uterine cancer	1.37e-05	2.88e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—HRAS—uterine cancer	1.37e-05	2.87e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—AKT1—uterine cancer	1.36e-05	2.87e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—KRAS—uterine cancer	1.36e-05	2.87e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—CDKN1B—uterine cancer	1.36e-05	2.87e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—NRAS—uterine cancer	1.36e-05	2.86e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—HRAS—uterine cancer	1.36e-05	2.86e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—PIK3CA—uterine cancer	1.35e-05	2.85e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—KRAS—uterine cancer	1.35e-05	2.84e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—CDKN1B—uterine cancer	1.35e-05	2.83e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—SOCS3—uterine cancer	1.34e-05	2.81e-05	CbGpPWpGaD
Ruxolitinib—JAK3—GPCR downstream signaling—AKT1—uterine cancer	1.33e-05	2.8e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—VEGFA—uterine cancer	1.33e-05	2.79e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—HRAS—uterine cancer	1.33e-05	2.79e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—HRAS—uterine cancer	1.32e-05	2.79e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—CDKN1B—uterine cancer	1.32e-05	2.78e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—ERBB2—uterine cancer	1.32e-05	2.77e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—NRAS—uterine cancer	1.31e-05	2.76e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—AKT1—uterine cancer	1.31e-05	2.76e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—AKT1—uterine cancer	1.3e-05	2.74e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—ESR1—uterine cancer	1.3e-05	2.73e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—CTNNB1—uterine cancer	1.29e-05	2.71e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CDH1—uterine cancer	1.28e-05	2.7e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—CDKN1B—uterine cancer	1.28e-05	2.7e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CDKN2B—uterine cancer	1.28e-05	2.69e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—PIK3CA—uterine cancer	1.27e-05	2.68e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—CTNNB1—uterine cancer	1.27e-05	2.68e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—HRAS—uterine cancer	1.27e-05	2.67e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—KRAS—uterine cancer	1.27e-05	2.67e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—ESR1—uterine cancer	1.26e-05	2.65e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—PTEN—uterine cancer	1.25e-05	2.64e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—PIK3CA—uterine cancer	1.25e-05	2.64e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—HRAS—uterine cancer	1.25e-05	2.63e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—ERBB2—uterine cancer	1.25e-05	2.63e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—CTNNB1—uterine cancer	1.25e-05	2.63e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IGF1R—uterine cancer	1.24e-05	2.61e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—PIK3CA—uterine cancer	1.24e-05	2.61e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—AKT1—uterine cancer	1.24e-05	2.61e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—PTEN—uterine cancer	1.24e-05	2.61e-05	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—CXCL8—uterine cancer	1.24e-05	2.6e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—ERBB2—uterine cancer	1.23e-05	2.59e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—CDKN1B—uterine cancer	1.22e-05	2.57e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—ESR1—uterine cancer	1.22e-05	2.57e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—PTEN—uterine cancer	1.22e-05	2.56e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—KRAS—uterine cancer	1.22e-05	2.56e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—CTNNB1—uterine cancer	1.21e-05	2.55e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—AKT1—uterine cancer	1.21e-05	2.55e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—AKT1—uterine cancer	1.21e-05	2.54e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—AKT1—uterine cancer	1.21e-05	2.54e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—TP53—uterine cancer	1.2e-05	2.53e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—AKT1—uterine cancer	1.2e-05	2.52e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—EP300—uterine cancer	1.2e-05	2.52e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—NRAS—uterine cancer	1.19e-05	2.5e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CXCL8—uterine cancer	1.19e-05	2.5e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—EP300—uterine cancer	1.18e-05	2.49e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—PTEN—uterine cancer	1.18e-05	2.49e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—HRAS—uterine cancer	1.18e-05	2.48e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—AKT1—uterine cancer	1.17e-05	2.47e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—HRAS—uterine cancer	1.17e-05	2.46e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—KRAS—uterine cancer	1.17e-05	2.46e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—AKT1—uterine cancer	1.17e-05	2.46e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—SMAD3—uterine cancer	1.17e-05	2.46e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CXCL8—uterine cancer	1.17e-05	2.45e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—PIK3CA—uterine cancer	1.16e-05	2.45e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—EP300—uterine cancer	1.16e-05	2.44e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—HRAS—uterine cancer	1.16e-05	2.44e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CDKN1B—uterine cancer	1.16e-05	2.44e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—CTNNB1—uterine cancer	1.15e-05	2.43e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—HRAS—uterine cancer	1.15e-05	2.42e-05	CbGpPWpGaD
Ruxolitinib—JAK1—GPCR downstream signaling—AKT1—uterine cancer	1.15e-05	2.41e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CCL2—uterine cancer	1.14e-05	2.4e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CDKN1B—uterine cancer	1.14e-05	2.4e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—KRAS—uterine cancer	1.13e-05	2.37e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—GPCR downstream signaling—AKT1—uterine cancer	1.13e-05	2.37e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—EP300—uterine cancer	1.13e-05	2.37e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—PTEN—uterine cancer	1.12e-05	2.37e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—CXCL8—uterine cancer	1.12e-05	2.36e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—AKT1—uterine cancer	1.12e-05	2.36e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—VEGFA—uterine cancer	1.12e-05	2.36e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—NRAS—uterine cancer	1.12e-05	2.36e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—PIK3CA—uterine cancer	1.12e-05	2.35e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—FGFR2—uterine cancer	1.11e-05	2.34e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CCL2—uterine cancer	1.11e-05	2.33e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—NRAS—uterine cancer	1.11e-05	2.33e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—AKT1—uterine cancer	1.11e-05	2.33e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—STAR—uterine cancer	1.1e-05	2.31e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—AKR1B1—uterine cancer	1.1e-05	2.31e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CTNNB1—uterine cancer	1.09e-05	2.3e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—NRAS—uterine cancer	1.09e-05	2.29e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—ERBB2—uterine cancer	1.08e-05	2.28e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—HRAS—uterine cancer	1.08e-05	2.27e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CTNNB1—uterine cancer	1.08e-05	2.26e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—PIK3CA—uterine cancer	1.07e-05	2.26e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CCL2—uterine cancer	1.07e-05	2.26e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—EP300—uterine cancer	1.07e-05	2.26e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—PTEN—uterine cancer	1.07e-05	2.24e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—NRAS—uterine cancer	1.05e-05	2.22e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—PTEN—uterine cancer	1.05e-05	2.21e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—AKT1—uterine cancer	1.04e-05	2.19e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—PIK3CA—uterine cancer	1.04e-05	2.18e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—HRAS—uterine cancer	1.03e-05	2.18e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—AKT1—uterine cancer	1.03e-05	2.18e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—KRAS—uterine cancer	1.02e-05	2.15e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—AKT1—uterine cancer	1.02e-05	2.15e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—EP300—uterine cancer	1.02e-05	2.14e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—AKT1—uterine cancer	1.01e-05	2.13e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—NRAS—uterine cancer	1e-05	2.11e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—TP53—uterine cancer	1e-05	2.11e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CDKN1B—uterine cancer	1e-05	2.11e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—EP300—uterine cancer	1e-05	2.11e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—ERBB2—uterine cancer	1e-05	2.1e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—HRAS—uterine cancer	9.94e-06	2.09e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—VEGFA—uterine cancer	9.64e-06	2.03e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—KRAS—uterine cancer	9.64e-06	2.03e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—HRAS—uterine cancer	9.59e-06	2.02e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—ESR1—uterine cancer	9.54e-06	2.01e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—KRAS—uterine cancer	9.52e-06	2e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—NRAS—uterine cancer	9.52e-06	2e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—ERBB2—uterine cancer	9.51e-06	2e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—AKT1—uterine cancer	9.51e-06	2e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—VEGFA—uterine cancer	9.48e-06	1.99e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CTNNB1—uterine cancer	9.47e-06	1.99e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—PIK3CA—uterine cancer	9.41e-06	1.98e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—NRAS—uterine cancer	9.36e-06	1.97e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—KRAS—uterine cancer	9.35e-06	1.97e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—CDKN1B—uterine cancer	9.26e-06	1.95e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—ERBB2—uterine cancer	9.24e-06	1.94e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—PTEN—uterine cancer	9.23e-06	1.94e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—AKT1—uterine cancer	9.13e-06	1.92e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—KRAS—uterine cancer	9.07e-06	1.91e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CXCL8—uterine cancer	9.02e-06	1.9e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—NRAS—uterine cancer	9.01e-06	1.9e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—ERBB2—uterine cancer	8.96e-06	1.88e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—PIK3CA—uterine cancer	8.85e-06	1.86e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CDKN1B—uterine cancer	8.81e-06	1.85e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—EP300—uterine cancer	8.8e-06	1.85e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—AKT1—uterine cancer	8.78e-06	1.85e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CXCL8—uterine cancer	8.76e-06	1.84e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—PIK3CA—uterine cancer	8.75e-06	1.84e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—CTNNB1—uterine cancer	8.75e-06	1.84e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—HRAS—uterine cancer	8.7e-06	1.83e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—KRAS—uterine cancer	8.64e-06	1.82e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—POLD1—uterine cancer	8.6e-06	1.81e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—PIK3CA—uterine cancer	8.59e-06	1.81e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CDKN1B—uterine cancer	8.55e-06	1.8e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—PTEN—uterine cancer	8.52e-06	1.79e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CXCL8—uterine cancer	8.5e-06	1.79e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—AKT1—uterine cancer	8.47e-06	1.78e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—TP53—uterine cancer	8.46e-06	1.78e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CCL2—uterine cancer	8.4e-06	1.77e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—PIK3CA—uterine cancer	8.34e-06	1.75e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CTNNB1—uterine cancer	8.32e-06	1.75e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CDKN1B—uterine cancer	8.3e-06	1.75e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—NRAS—uterine cancer	8.24e-06	1.73e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—KRAS—uterine cancer	8.19e-06	1.72e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—HRAS—uterine cancer	8.19e-06	1.72e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—EP300—uterine cancer	8.13e-06	1.71e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—PTEN—uterine cancer	8.11e-06	1.71e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—HRAS—uterine cancer	8.09e-06	1.7e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CTNNB1—uterine cancer	8.08e-06	1.7e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—KRAS—uterine cancer	8.06e-06	1.7e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—AKR1C1—uterine cancer	8.05e-06	1.69e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—HRAS—uterine cancer	7.95e-06	1.67e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—PIK3CA—uterine cancer	7.93e-06	1.67e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—PTEN—uterine cancer	7.88e-06	1.66e-05	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—PIK3CA—uterine cancer	7.85e-06	1.65e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CTNNB1—uterine cancer	7.84e-06	1.65e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—KRAS—uterine cancer	7.76e-06	1.63e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—EP300—uterine cancer	7.74e-06	1.63e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—HRAS—uterine cancer	7.71e-06	1.62e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—AKT1—uterine cancer	7.68e-06	1.62e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PTEN—uterine cancer	7.64e-06	1.61e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—NRAS—uterine cancer	7.6e-06	1.6e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—PIK3CA—uterine cancer	7.53e-06	1.58e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—EP300—uterine cancer	7.51e-06	1.58e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—PIK3CA—uterine cancer	7.4e-06	1.56e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—HRAS—uterine cancer	7.34e-06	1.54e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—VEGFA—uterine cancer	7.33e-06	1.54e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—EP300—uterine cancer	7.29e-06	1.53e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—TP53—uterine cancer	7.28e-06	1.53e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—NRAS—uterine cancer	7.24e-06	1.52e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—AKT1—uterine cancer	7.23e-06	1.52e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—RRM2—uterine cancer	7.17e-06	1.51e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—TP53—uterine cancer	7.16e-06	1.51e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—AKT1—uterine cancer	7.15e-06	1.5e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—PIK3CA—uterine cancer	7.13e-06	1.5e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—VEGFA—uterine cancer	7.11e-06	1.5e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—KRAS—uterine cancer	7.09e-06	1.49e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—NRAS—uterine cancer	7.03e-06	1.48e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—AKT1—uterine cancer	7.02e-06	1.48e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—ERBB2—uterine cancer	7e-06	1.47e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—HRAS—uterine cancer	6.96e-06	1.46e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—DCN—uterine cancer	6.96e-06	1.46e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—VEGFA—uterine cancer	6.9e-06	1.45e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—HRAS—uterine cancer	6.85e-06	1.44e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—NRAS—uterine cancer	6.82e-06	1.43e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—AKT1—uterine cancer	6.81e-06	1.43e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CXCL8—uterine cancer	6.64e-06	1.4e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—HRAS—uterine cancer	6.59e-06	1.39e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CYP11A1—uterine cancer	6.56e-06	1.38e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—KRAS—uterine cancer	6.55e-06	1.38e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—PIK3CA—uterine cancer	6.51e-06	1.37e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CDKN1B—uterine cancer	6.48e-06	1.36e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—AKT1—uterine cancer	6.48e-06	1.36e-05	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—AKT1—uterine cancer	6.41e-06	1.35e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—KRAS—uterine cancer	6.23e-06	1.31e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—AKR1C3—uterine cancer	6.19e-06	1.3e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—AKT1—uterine cancer	6.15e-06	1.29e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CTNNB1—uterine cancer	6.12e-06	1.29e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—KRAS—uterine cancer	6.05e-06	1.27e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—AKT1—uterine cancer	6.05e-06	1.27e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—HRAS—uterine cancer	6.03e-06	1.27e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—PIK3CA—uterine cancer	6.01e-06	1.27e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PTEN—uterine cancer	5.97e-06	1.26e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—KRAS—uterine cancer	5.87e-06	1.23e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—AKT1—uterine cancer	5.82e-06	1.23e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—PIK3CA—uterine cancer	5.72e-06	1.2e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—EP300—uterine cancer	5.69e-06	1.2e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—HRAS—uterine cancer	5.56e-06	1.17e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—PIK3CA—uterine cancer	5.56e-06	1.17e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—TP53—uterine cancer	5.54e-06	1.16e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—VEGFA—uterine cancer	5.39e-06	1.13e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PIK3CA—uterine cancer	5.39e-06	1.13e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—TP53—uterine cancer	5.38e-06	1.13e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—NRAS—uterine cancer	5.33e-06	1.12e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—AKT1—uterine cancer	5.32e-06	1.12e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—HRAS—uterine cancer	5.3e-06	1.11e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—TP53—uterine cancer	5.21e-06	1.1e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—HRAS—uterine cancer	5.14e-06	1.08e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—HRAS—uterine cancer	4.99e-06	1.05e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—AKT1—uterine cancer	4.91e-06	1.03e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—STK11—uterine cancer	4.83e-06	1.02e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CYP19A1—uterine cancer	4.83e-06	1.02e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—AKT1—uterine cancer	4.68e-06	9.84e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—KRAS—uterine cancer	4.58e-06	9.64e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—AKT1—uterine cancer	4.54e-06	9.55e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—AKT1—uterine cancer	4.4e-06	9.26e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PIK3CA—uterine cancer	4.21e-06	8.86e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TP53—uterine cancer	4.07e-06	8.57e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—HRAS—uterine cancer	3.9e-06	8.2e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—MTHFR—uterine cancer	3.63e-06	7.63e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—AKT1—uterine cancer	3.44e-06	7.24e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PTEN—uterine cancer	2.02e-06	4.24e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—EP300—uterine cancer	1.92e-06	4.05e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PIK3CA—uterine cancer	1.42e-06	2.99e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—AKT1—uterine cancer	1.16e-06	2.45e-06	CbGpPWpGaD
